***Background.*** Community-acquired bacterial pneumonia (CABP) is a serious infection in many patients. Ceftaroline fosamil (CPT-F) is approved for the treatment of CABP and acute bacterial skin and skin structure infections in the US, and for similar indications in the EU. CAPTURE is a multicenter registry study describing patients treated with CPT-F in the US.

***Methods.*** Data were collected at participating centers by randomly ordered chart review between September 2011 and February 2014, which included demographics, disease characteristics, antibiotic use, location of care, and clinical response. Evaluable patients (pts) were those with a clinical outcome determined.

***Results.*** 649 pts were evaluable. Demographics and co-morbidities are presented in the table. On diagnosis 81% of pts had 2 or more signs and symptoms; most common were dyspnea (76%), cough (65%), abnormal auscultatory findings (63%), and sputum production (46%). At initiation of CPT-F treatment, 35% were located in an intensive care unit (ICU). 84% received prior antibiotics; most commonly ceftriaxone (35%), vancomycin (31%), azithromycin (27%) and levofloxacin (26%). The mean duration of CPT-F therapy was 6.1 days (SD ± 3.8). Concurrent antibiotics were used in 64% and included azithromycin (23%), levofloxacin (17%) and vancomycin (8%). Overall clinical success was 83%; 73% in the ICU and 88% in the ward. Clinical success with CPT-F monotherapy was 84%, and with concurrent therapy, 83%. Clinical success was 85% for CPT-F as first line therapy and 83% as 2nd line therapy. CPT-F was discontinued in 8 (1%) pts due to an adverse event. The majority of pts were discharged to home (60%) or to another healthcare facility (35%).

  -----------------------------------------------------
  Demographics and Co-morbidities   Pts (N=649) n (%)
  --------------------------------- -------------------
  Males, Females                    315 (49)\
                                    334 (51)

  Age, years, mean (SD), range      63.4 (17.5)\
                                    18--99

  Pts with co-morbidities           514 (79)

  Structural lung disease           276 (43)

  Smoking                           223 (34)

  Gastroesophageal reflux           146 (22)

  Prior pneumonia                   159 (24)

  Congestive heart failure          134 (21)

  Cerebrovascular accident          53 (8)

  Alcoholism                        54 (8)
  -----------------------------------------------------

***Conclusion.*** Contemporary clinical use of CPT-F for treating CABP show high rates of clinical success including pts in the ICU. CAPTURE data support the use of CPT-F as an important antibiotic for treatment of complicated CABP.
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